DRG Market Assessment 보고서

Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem-cell transplants (HSCTs). The systemic inflammatory reaction is triggered by donor T…

MARKET OUTLOOK Bipolar disorder (BPD) is a debilitating psychiatric illness that is increasingly considered to be a spectrum disorder. Patients experience symptoms ranging in severity from…

In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…

Faced with the financial pressures of reimbursing a robust pipeline of new and expensive cancer therapies, U.S. managed care organizations (MCOs) are increasing their focus on managing the…

Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. In this series, we track…

MARKET OUTLOOKLow testosterone is a condition characterized by impaired spermatogenesis and low serum testosterone. In adult men, low testosterone can be caused by intrinsic…

Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…

Atopic dermatitis (AD) is a chronic, pediatric-onset, inflammatory skin disease marked principally by pruritus and eczema. Topical agents (e.g., corticosteroids) are the mainstays of prescription…

Introduction: This research explores the reimbursement and utilization landscape for acute coronary syndrome (ACS) drugs and the impact of accountable care organizations (ACOs) on payers’ and…

Based on DRG’s gold-standard Epidemiology data, the Interactive Patient Flow Model provides insight into the epidemiology of HCV for five different treatment scenarios.With the introduction of…

For the estimated 3 million people in the United States who have Alzheimer’s disease (AD), approved treatment is limited to five procognitive symptomatic therapies (e.g., donepezil, memantine)…

Retinitis pigmentosa (RP) is a rare genetic disorder marked by retinal degeneration, progressive vision loss, and eventual blindness. There are no approved pharmacotherapies for RP, and current…